Stockholm X October, 2025
TIRmed Pharma, a biotechnology company developing innovative treatments for
autoimmune skin diseases, has expanded its collaboration with Zelmic, a leading
specialist in formulation development. The partnership covers GMP development and
manufacturing of TIRmed’s topical drug candidate TIR-C for the treatment of atopic
dermatitis (eczema), aiming to ensure high product quality ahead of upcoming clinical
trials.
TIRmed Pharma is developing a new treatment for atopic dermatitis, with the goal of offering
patients an effective therapy with fewer side effects and easier administration. The treatment
targets the underlying causes of the disease rather than merely alleviating symptoms and
has shown highly promising preclinical results – five topical applications over two weeks
have provided up to 15 months of symptom relief.
As part of its clinical development program, TIRmed Pharma is now working with Zelmic to
establish GMP-compliant manufacturing processes for TIR-C. The extended collaboration
includes both formulation and production of clinical trial material, focusing on product quality,
stability, and regulatory compliance ahead of the planned Phase Ib/IIa study.
“The expanded partnership with Zelmic marks a milestone in the clinical development of TIR-
C,” says Leo Holmgren, CEO of TIRmed Pharma. “Zelmic’s deep expertise in topical
formulation development strengthens the foundation for our clinical program and supports
our mission to improve treatment outcomes for patients with atopic dermatitis worldwide.”
“We are delighted to continue supporting TIRmed Pharma in developing this promising drug
candidate,” says David Sagna, CEO of Zelmic. “Reliable manufacturing and analytical
processes are crucial to ensuring quality and consistency ahead of entering clinical
development, and we look forward to contributing our formulation expertise to this important
project.”
About TIRmed Pharma
TIRmed Pharma is a biotechnology company developing next-generation immunomodulatory
therapies for autoimmune skin diseases, with an initial focus on Atopic Dermatitis (eczema).
The company’s drug candidate, TIR-C, is a topical oligonucleotide-based treatment that
regulates immune responses and targets the disease’s underlying mechanisms rather than
just controlling symptoms. Promising preclinical results support its potential to provide long-
lasting relief and reduce treatment burden. Building on expertise in immunology and drug
development, the company is pioneering new solutions in dermatological immunotherapy to
enable more targeted and effective treatment options.
TIRmed Pharma is headquartered in Stockholm, Sweden. For more information, visit
tirmedpharma.com and follow TIRmed on LinkedIn.
About Zelmic
Zelmic AB is a specialist CRO and CDMO focused on topical and transdermal drug
development. Based in Lund, Sweden, the company offers end-to-end services from
formulation and analytical development to IVRT/IVPT testing and GMP manufacturing of
clinical materials. With deep expertise in semisolid formulations and regulatory compliance,
Zelmic helps pharma and biotech partners turn topical drug concepts into effective, market-
ready products.
For more information, visit zelmic.se.